Amneal Pharmaceuticals Inc. has announced that its subsidiary, Amneal Pharmaceuticals LLC, has priced a private offering of $600 million in senior secured notes due 2032, with an interest rate of 6.875%. The offering was adjusted down from an initially planned $750 million, in conjunction with an increase in the term loan facility. Concurrently, Amneal plans to borrow $2.1 billion in new seven-year term B loans under a new term loan facility. The proceeds from these financial activities will be used to refinance existing term B loans, repay outstanding amounts under the ABL facility, and cover related expenses. The notes, offered at 100% of their principal amount, are expected to close on August 1, 2025, subject to customary closing conditions.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。